Commodity Chemicals

FENGBEI BIOTECH

FENGBEI BIOTECH to Release FY2025 Earnings on May 20, 2026 (BJT)

FENGBEI BIOTECH released FY2026 Q1 earnings on April 28 (BJT), actual revenue CNY 1.109 B, actual EPS CNY 0.28

FENGBEI BIOTECH released FY2025 earnings on April 9 (BJT) with actual revenue of CNY 3.171 B and EPS of CNY 1.24

FENGBEI BIOTECH released FY2025 Q4 earnings on April 9 (BJT), actual revenue CNY 919.39 M, actual EPS CNY 0.1781

FENGBEI BIOTECH released FY2025 Q3 earnings on November 3 (BJT), actual revenue CNY 773.28 M, actual EPS CNY 0.3357

FENGBEI BIOTECH released FY2025 9 Months earnings on November 3, 2025 (BJT), with actual revenue of CNY 2.251 B and actual EPS of CNY 1.0757

FENGBEI BIOTECH released FY2024 earnings on October 16, 2025 (BJT) with actual revenue of CNY 1.948 B and EPS of CNY 1.15

FENGBEI BIOTECH released FY2024 9 Months Earnings on October 16, 2025 (BJT), with actual revenue of CNY 1.387 B and EPS of CNY 0.8083

FENGBEI BIOTECH released FY2024 Q4 earnings on October 16, 2025 (BJT), with actual revenue of CNY 560.97 M and EPS of CNY 0.3387

FENGBEI BIOTECH released FY2024 Q3 earnings on October 16, 2025 (BJT), with actual revenue of CNY 399.15 M and EPS of CNY 0.1683

FENGBEI BIOTECH released FY2022 earnings on October 16, 2025 (BJT) with actual revenue of CNY 1.709 B and EPS of CNY 1.26

FENGBEI BIOTECH released FY2025 Q1 earnings on October 16 (BJT), actual revenue CNY 739.06 M, actual EPS CNY 0.37

FENGBEI BIOTECH released FY2025 Semi-Annual earnings on October 16, 2025 (BJT), actual revenue CNY 1.478 B, actual EPS CNY 0.74

FENGBEI BIOTECH released FY2025 Q2 earnings on October 16, 2025 (BJT), with actual revenue of CNY 739.06 M and EPS of CNY 0.37

FENGBEI BIOTECH released FY2024 Q1 earnings on December 30, 2024 (BJT), with actual revenue of CNY 493.95 M and EPS of CNY 0.32

FENGBEI BIOTECH released FY2024 Semi-Annual earnings on December 30 (BJT), actual revenue CNY 987.89 M, actual EPS CNY 0.64

FENGBEI BIOTECH released FY2024 Q2 earnings on December 30, 2024 (BJT) with actual revenue of CNY 493.95 M and EPS of CNY 0.32

FENGBEI BIOTECH released FY2023 earnings on December 30, 2024 (BJT), with actual revenue of CNY 1.728 B and actual EPS of CNY 1.21

Earning Release Date

财报预告

FY2025 Annual Earning Release Today 2026.05.20

513120

516610

589720

603334

JD HEALTH has reached a deep cooperation with Beijing Dingfeng Biotechnology to jointly create an integrated health management solution that covers screening, diagnosis, treatment, medication, follow-up, and protection. By integrating digital technology and industrial resources, both parties will improve the full-cycle health services and explore sustainable development. JD HEALTH will leverage its advantages in the pharmaceutical supply chain and integrated online and offline services to collaborate deeply with Dingfeng Biotechnology in areas such as drug accessibility, health knowledge dissemination, and patient management

AASTOCKS

GF CSI HK Innovative Drugs Industry ETF(QDII)

Dacheng CSI All Share Health Care Equipment and Services ETF

Guotai SSE STAR Brand Name Drug ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Merchants CSI All Share Medical Apparatus and Instruments ETF

China Universal 800 Health Care ETF

ESSEX BIO-TECH

JD HEALTH

ChinaAMC CSI All Share Health Care Devices ETF

E Fund CSI 300 Health Care ETF

JD HEALTH and Pinnacle Bio have reached a cooperation on integrated health management solutions

According to the Zhitong Finance APP, FENGBEI BIOTECH announced that its stock will be listed on the main board of the Shanghai Stock Exchange on November 5, 2025

Zhitong

FENGBEI BIOTECH stock will be listed on the Shanghai Stock Exchange main board on November 5

FENGBEI BIOTECH announced that its 35.9 million new shares will be listed on the Shanghai Stock Exchange main board on November 5, 2025, with the stock code 603334. The company reminds investors to pay attention to various risks in the early stages of listing, including the relaxation of price fluctuation limits, low circulating shares, valuation, and margin financing risks. The issuance price is set at 24.49 yuan per share, corresponding to a diluted price-to-earnings ratio of 30.47 times for 2024 after deducting non-recurring items, which is lower than the industry average and the average level of comparable companies

FENGBEI BIOTECH: 35.9 million new shares will be listed on the main board on November 5, highlighting multiple risks

Today, FENGBEI BIOTECH is available for subscription, with an issuance price-to-earnings ratio of 30.47 times, subscription code 732334, subscription price of 24.49 yuan, and a single account subscription limit of 11,000 shares

New Stock Alert: FENGBEI BIOTECH is available for subscription today

FENGBEI BIOTECH started its subscription on October 27, with an issue price of 24.49 yuan per share, a subscription limit of 11,000 shares, and a price-to-earnings ratio of 30.47 times. The company focuses on the comprehensive utilization of waste oil resources, with an existing biodiesel production capacity of 105,000 tons, ranking sixth in the industry. From 2022 to 2024, the company's operating revenues are projected to be 1.709 billion yuan, 1.728 billion yuan, and 1.948 billion yuan, with net profits of 133 million yuan, 130 million yuan, and 124 million yuan, respectively. The net cash flow from operating activities is expected to decline in 2024

A-share subscription | FENGBEI BIOTECH starts subscription with existing biodiesel production capacity of 105,000 tons

603092

According to the current issuance schedule, there are 3 new stocks available for subscription next week, including 2 new stocks on the Shanghai Stock Exchange and 1 new stock on the Beijing Stock Exchange. From the schedule, investors can subscribe to the new Shanghai Stock Exchange stock FENGBEI BIOTECH on Monday, and the new Beijing Stock Exchange stock Zhongcheng Consulting and the new Shanghai Stock Exchange stock Transmission Technology on Tuesday

DLJ Transmission

Next week, there are 3 new stocks available for subscription

FENGBEI BIOTECH(603334.SH)